Article révisé par les pairs
Titre:
  • The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Auteur:Zeuzem, Stefan; Buggisch, Peter; Agarwal, Kosh; Marcellin, P; Sereni, Daniel; Klinker, Hartwig; Moreno, Christophe; Zarski, Jean-Pierre; Horsmans, Y.; Mo, Hongmei; Arterburn, Sarah; Knox, Steven; Oldach, David; McHutchison, John G; Manns, Michael P; Foster, Graham R
Informations sur la publication:Hepatology, 55, 3, page (749-758)
Statut de publication:Publié, 2012-03
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Antiviral Agents -- therapeutic use
Dose-Response Relationship, Drug
Drug Therapy, Combination
Enzyme Inhibitors -- therapeutic use
Female
Genotype
Hepacivirus -- genetics
Hepatitis C -- blood -- drug therapy
Humans
Interferon-alpha -- therapeutic use
Male
Middle Aged
Peptides, Cyclic -- therapeutic use
Phosphinic Acids -- therapeutic use
Polyethylene Glycols -- therapeutic use
Protease Inhibitors -- therapeutic use
Purines -- therapeutic use
Pyridazines -- therapeutic use
RNA, Viral -- blood
Recombinant Proteins -- therapeutic use
Ribavirin -- therapeutic use
Treatment Outcome
Note générale:Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
FLWIN
Langue:Anglais
Identificateurs:urn:issn:0270-9139
info:doi/10.1002/hep.24744
info:scp/84857415002
info:pmid/22006408

Documents en relation

DI-fusion